Heron Therapeutics Announces Poster Presentations of Data from Phase 2 Clinical Program for HTX-011 at PAINWeek® 2016
August 29 2016 - 8:00AM
Business Wire
Heron Therapeutics, Inc. (NASDAQ: HRTX), a biotechnology company
focused on improving the lives of patients by developing
best-in-class medicines that address major unmet medical needs,
today announced that preliminary, positive, top-line results from
Heron’s Phase 2 study of HTX-011 in patients undergoing inguinal
hernia repair will be presented in two posters at PAINWeek®, the
national conference on pain for frontline practitioners, on
Thursday, September 8, 2016 in Las Vegas, NV.
Presentation details are as follows:
Poster Title:
Local Administration of HTX-011, a
Long-Acting Biochronomer-Based Bupivacaine/Meloxicam Combination,
in Hernia Repair: Initial Results Author/Presenter:
Peter J. Winkle, MD, FACP, CPI, FACG,
Anaheim Regional Medical Center, Anaheim Clinical Research
Poster Number:
144 Date/Time:
Thursday, September 8, 2016 from 6:30
PM – 8:30 PM PT Location:
Level 3, Gracia 7
Poster Title:
Local Administration of HTX-011, a Long-Acting Biochronomer-Based
Bupivacaine/Meloxicam Combination, in Hernia Repair Provides
Similar Initial Results Whether Injected, Instilled, or Both
Author/Presenter:
Harold S. Minkowitz, MD, Diplomat American Board of
Anesthesiology, Department of Anesthesiology, Memorial Hermann
Memorial City Medical Center Poster Number:
90 Date/Time:
Thursday,
September 8, 2016 from 6:30 PM – 8:30 PM PT Location:
Level 3, Gracia 7
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a biotechnology company focused on
improving the lives of patients by developing best-in-class
medicines that address major unmet medical needs. Heron is
developing novel, patient-focused solutions that apply its
innovative science and technologies to already-approved
pharmacological agents for patients suffering from cancer or pain.
For more information, visit www.herontx.com.
Forward-Looking Statements
This news release contains "forward-looking statements" as
defined by the Private Securities Litigation Reform Act of 1995.
Heron cautions readers that forward-looking statements are based on
management’s expectations and assumptions as of the date of this
news release and are subject to certain risks and uncertainties
that could cause actual results to differ materially, including,
but not limited to, those associated with: whether the Phase 2
study results are indicative of the results in future studies
related to HTX-011, the sufficiency of the Phase 2 data to allow
the commencement of Phase 3 registration studies for HTX-011, the
potential market opportunity for HTX-011, and other risks and
uncertainties identified in the Company's filings with the
Securities and Exchange Commission. Forward-looking statements
reflect our analysis only on their stated date, and Heron takes no
obligation to update or revise these statements except as may be
required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160829005158/en/
Investor Relations and Media Contact:Heron Therapeutics,
Inc.Jennifer Capuzelo, 858-703-6063Associate Director, Investor
Relationsjcapuzelo@herontx.com
Heron Therapeautics (NASDAQ:HRTX)
Historical Stock Chart
From Apr 2024 to May 2024
Heron Therapeautics (NASDAQ:HRTX)
Historical Stock Chart
From May 2023 to May 2024